Avexxin

Recent Finacing

Series B

Recent Raise

Undisclosed

Avexxin is a Trondheim-based biopharmaceutical company developing small-molecule therapeutics for chronic inflammatory diseases, with a psoriasis candidate entering combined Phase I/IIa and preclinical rheumatoid arthritis and glomerulonephritis programs.